This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Weiss, Glen
| Item Type | Name |
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Protein Kinase C-alpha
|
|
Academic Article
|
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
|
|
Academic Article
|
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
|
|
Academic Article
|
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
|
|
Academic Article
|
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration.
|
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
|
Academic Article
|
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
|
|
Academic Article
|
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
|
|
Academic Article
|
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500?mg/m(2) every 21 days in patients with cancer.
|
|
Academic Article
|
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
|